Published in Hum Mol Genet on October 09, 2012
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab (2013) 0.96
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab (2014) 0.90
A multi-parametric workflow for the prioritization of mitochondrial DNA variants of clinical interest. Hum Genet (2015) 0.89
Persistent damage induces mitochondrial DNA degradation. DNA Repair (Amst) (2013) 0.87
Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours. Eur J Hum Genet (2013) 0.81
The "fast" and the "slow" modes of mitochondrial DNA degradation. Mitochondrial DNA (2014) 0.78
A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. BMC Cancer (2015) 0.78
Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dubé tumors. Mod Pathol (2015) 0.77
High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants. Am J Cancer Res (2015) 0.76
Identification and functional prediction of mitochondrial complex III and IV mutations associated with glioblastoma. Neuro Oncol (2015) 0.76
The Mitochondrial Complex(I)ty of Cancer. Front Oncol (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Triple-negative breast cancer. N Engl J Med (2010) 11.39
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol (2008) 5.10
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol (2010) 2.86
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat (2009) 2.85
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Genetic interactions in cancer progression and treatment. Cell (2011) 2.54
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res (2007) 2.12
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 2.09
Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis. Hum Pathol (2012) 2.09
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol (2003) 2.07
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2008) 2.06
Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol (2005) 2.06
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A (2007) 2.01
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol (2007) 2.00
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
'Spindle cell oncocytoma' of the adenohypophysis: a tumor of folliculostellate cells? Am J Surg Pathol (2002) 1.98
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab (2006) 1.98
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol (2009) 1.95
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Genetic heterogeneity and cancer drug resistance. Lancet Oncol (2012) 1.91
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med (2010) 1.90
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat (2007) 1.84
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer (2006) 1.82
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol (2010) 1.79
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol (2010) 1.79
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res (2007) 1.78
Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci (2004) 1.77
Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol (2008) 1.75
Ependymoma with neuropil-like islands: a case report with diagnostic and histogenetic implications. Acta Neuropathol (2004) 1.73
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells (2006) 1.72
Breast cancer precursors revisited: molecular features and progression pathways. Histopathology (2010) 1.72
Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women. Am J Epidemiol (2004) 1.71
Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol (2010) 1.70
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol (2005) 1.70
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 1.64
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol (2010) 1.63
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol (2006) 1.62
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest (2006) 1.59
Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem (2003) 1.59
Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control (2004) 1.59
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res (2005) 1.59
Histological types of breast cancer: how special are they? Mol Oncol (2010) 1.58
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics (2005) 1.52
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat (2008) 1.51
Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus (2007) 1.51
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res (2009) 1.49
Non-existence of caveolin-1 gene mutations in human breast cancer. Breast Cancer Res Treat (2011) 1.47
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45
Amyotrophic lateral sclerosis with mutation of the Cu/Zn superoxide dismutase gene (SOD1) in a patient with Down syndrome. Neuromuscul Disord (2007) 1.44
Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat (2010) 1.43
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol (2004) 1.43
A novel T137A SOD1 mutation in an Italian family with two subjects affected by amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.42